Neuroprotective Role of the Novel GLP-1R Agonist Semaglutide
Kenzheshova A. Moldasheva A. Aljofan M.
2025Bentham Science Publishers
Current Medicinal Chemistry
2025
Disturbances in insulin signaling and glucose metabolism within the brain are associated with the onset of neuronal degeneration and a reduction in synaptic activity. Research increasingly supports the therapeutic potential of GLP-1R agonists for diabetes-related neurodegenerative diseases. The incretin hormone recognized as GLP-1 is of major significance in ensuring the control of blood glucose levels and the facilitation of appropriate insulin signaling, which are also known to have neuroprotective properties against Alzheimers disease, including the prevention of neuronal death, inhibition of Aβ accumulation, and mitigation of tau hyperphosphorylation. In contrast to other types of GLP-1R agonists, limited studies have focused on the novel GLP-1R agonist Semaglutide. The principal aim of this review is to determine the molecular mechanisms that link Alzheimers disease and type 2 diabetes mellitus, as well as to understand the neuroprotective role of semaglutide.
Alzheimer’s disease , amyloid beta peptide , GLP-1R agonist , islet amyloid polypeptide , semaglutide , tau hyperphosphorylation , type 2 diabetes mellitus
Text of the article Перейти на текст статьи
Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
Drug Discovery and Development Laboratory, National Laboratory Astana, Astana, 010000, Kazakhstan
Department of Biomedical Sciences
Drug Discovery and Development Laboratory
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026